ImmunityBio Announces UAE Marketing Authorization for ANKTIVA

What Happened

• ImmunityBio, Inc. announced via press release dated July 29, 2026 (filed on Form 8‑K July 30, 2026) that the Emirates Drug Establishment (EDE) of the United Arab Emirates has granted marketing authorization for ANKTIVA® for two indications. The press release is furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Regulator: Emirates Drug Establishment (EDE), United Arab Emirates.
• Product: ANKTIVA® (ImmunityBio’s therapeutic candidate).
• Approval scope: Marketing authorization granted across two indications (as stated in the press release).
• Filing: Press release dated July 29, 2026 attached as Exhibit 99.1 to the Form 8‑K filed July 30, 2026.

Why It Matters

• A marketing authorization from the EDE is a regulatory milestone that permits ImmunityBio to market ANKTIVA in the UAE for the approved indications, potentially enabling commercial activity in that market. The 8‑K itself does not provide financial details, sales projections, or commercial terms; investors should review the attached press release for more specifics and monitor future disclosures for commercial and financial impact.